计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
避光,-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor
In Vitro
MRTX9768 inhibits SDMA and cell proliferation in HCT116 MTAP-del cells (SDMA IC 50 3 nM; prolif. IC 50 11 nM) with marked selectivity over HCT116 MTAP-WT cells (SDMA IC 50 544 nM; prolif. IC 50 861 nM). MRTX9768 (0-250 nM) results in LU99 SDMA inhibition maintaining after 3-hr drug treatment followed by 4-day washout (exhibiting tight binding and prolonged PRMT5•MTA occupancy). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In xenograft studies, oral administration of MRTX9768 demonstrates dose-dependent inhibition of SDMA in MTAP-del tumors, with less SDMA modulation observed in bone marrow . MRTX9768 selectively targets MTAP/CDKN2A-deleted tumors (such as glioblastoma). MRTX9768 (PO dose 30 mg/kg in CD-1 mouse and beagle dog, 10 mg/kg in cynomolgus monkey) has a favorable ADME profile (>50% bioavailability in mice and dogs, moderate to high clearance, No changes in RBC parameters when administered well above efficacious concentrations (1000 mg/kg)). MRTX9768 (100 mg/kg, orally, BID, 6/21 days) results in SDMA inhibition maintaining 3 days after dosing is stopped. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:PRMT5•MTA
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|